<DOC>
	<DOCNO>NCT00404092</DOCNO>
	<brief_summary>This study investigate safety tolerability well efficacy pharmacokinetics caspofungin four escalate dosage adult patient hematologic malignancy prove probable invasive aspergillosis .</brief_summary>
	<brief_title>Caspofungin Maximum Tolerated Dose Patients With Invasive Aspergillosis</brief_title>
	<detailed_description>Due efficacy broad antifungal spectrum relevant fungal pathogen , lack cross-resistance azoles amphotericin B , document efficacy human Aspergillus infection , favorable pharmacokinetic property , excellent tolerability accord current data , caspofungin highly promising candidate improve result treatment invasive fungal infection . Preclinical clinical data indicate dose dependent antifungal efficacy caspofungin well echinocandins micafungin anidulafungin . Thus appear reasonable investigate impact high dos caspofungin improve result already achieve component far . The maximum tolerated dose ( MTD ) caspofungin distribution drug patient follow administration dose 70 mg yet know . We therefore investigate safety , tolerability pharmacokinetics caspofungin rise dos dose escalation study adult patient proven probable invasive aspergillosis .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Immunocompromised due hematologic malignancy , bone marrow failure syndrome , hematopoietic stem cell transplantation , solid organ transplantation , condition result severe neutropenia , HIV infection , prolong corticosteroid therapy , treatment immunosuppressive medication , immunocompromising condition place patient risk invasive fungal infection . Evidence proven probable invasive aspergillosis , modify EORTC criterion Concomitant systemic antifungal agent permit study . Chronic invasive fungal infection , define signs/symptoms invasive fungal infection present &gt; 4 week precede entry study Prior systemic therapy ≥ 4 day polyene antifungal agent within 14 day study enrollment Prior systemic therapy ≥ 4 day nonpolyenes current , documented IFI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>aspergillosis</keyword>
	<keyword>caspofungin</keyword>
	<keyword>maximum tolerate dose</keyword>
</DOC>